Thymosin beta-4 (TB-4)

Thymosin beta-4 (Tβ4) is a naturally occurring, 43-amino-acid peptide involved in cell movement and tissue repair. It binds actin, a building block of the cell skeleton, and has activities that promote cell migration, blood-vessel formation and cell survival [1]. Its recovery literature includes measured improvements in wound closure, ligament mechanics and organ function in animals, alongside small human studies of topical treatment [2][3][4][5][6]. These findings concern full-length Tβ4; TB-500 is an acetylated seven-amino-acid fragment with a separate evidence base [10].

Skin wounds and burns. In rats with full-thickness skin wounds, topical or intraperitoneal Tβ4 increased re-epithelialization, the growth of a new skin covering, by 42% over saline controls at day 4 and up to 61% at day 7. Treated wounds also contracted more and showed increased collagen deposition and new blood vessels. These are improvements in specific healing measurements, rather than a 61% reduction in total healing time [2]. In diabetic mice with deep second-degree burns, local injections improved wound closure, granulation tissue and vascularization, with reduced expression of RAGE, a receptor implicated in diabetic tissue damage [11].

Ligament and muscle injury. A rat study placed Tβ4 in a fibrin sealant directly into a surgically cut medial collateral ligament. At four weeks, the repair tissue had more evenly organized collagen bundles, larger collagen fibrils and better mechanical properties than controls [3]. Muscle research is more mechanistic: Tβ4 expression rose in injured mouse skeletal muscle, while Tβ4 and its oxidized form increased migration of muscle precursor cells in culture. That supports a role in recruiting cells for repair, but the study did not establish faster recovery of muscle strength after treatment [12]. Local delivery into a rat ligament and cell-culture migration also do not establish that systemic injections heal human tendon tears or muscle strains.

Heart and brain injury. After experimentally induced heart attacks in mice, Tβ4 increased early survival of heart-muscle cells and improved cardiac function, associated with activation of the ILK–Akt survival pathway [4]. In rats with traumatic brain injury, treatment starting 24 hours after injury improved sensorimotor performance and spatial learning during a 35-day study. It reduced hippocampal cell loss and increased markers of new neurons and blood vessels, but did not reduce the volume of the brain lesion [5]. These experiments show functional recovery as well as tissue changes, although both remain animal findings.

Human skin-wound healing. A double-blind, placebo-controlled phase 2 study randomized 73 people with venous leg ulcers to topical Tβ4 or placebo. The authors reported a possible healing benefit with the 0.03% concentration, particularly for smaller or less severe wounds, and acceptable tolerability comparable to placebo. The published abstract does not give a between-group effect estimate or significance test for healing, so this is a preliminary clinical signal rather than an established treatment effect [6].

Corneal repair and dry eye. Topical Tβ4 accelerated resurfacing and reduced inflammatory-cell infiltration after chemical burns to mouse corneas [13]. A human trial of 0.1% Tβ4 eye drops (RGN-259) studied persistent corneal wounds in neurotrophic keratopathy, where impaired nerve supply disrupts healing. Complete closure at four weeks occurred in 6 of 10 treated patients versus 1 of 8 on placebo. The primary comparison did not reach statistical significance (P=0.0656); the trial stopped early because of slow recruitment, enrolling 18 of a planned 46 patients. A later assessment favored treatment, but corneal sensitivity did not improve, so wound closure should not be interpreted as demonstrated nerve regeneration [7]. In dry eye, a nine-patient trial found less discomfort and corneal staining [14]. A separate 72-patient trial missed both primary endpoints, although some secondary and ad hoc analyses favored treatment [8].

What this means for injury recovery. The preclinical evidence supports several repair activities, including skin resurfacing, collagen organization and recovery of function. Human trials of topical skin and eye treatment provide preliminary clinical evidence [6][7]. Controlled evidence that injected Tβ4 speeds human tendon, ligament or muscle recovery is still lacking. In a retrospective knee-pain report, three of four people given Tβ4 together with BPC-157 reported improvement, but there was no control group or imaging confirmation of tissue repair, and Tβ4's contribution cannot be separated from BPC-157 [15]. Intravenous phase 1 studies found short-term tolerability in healthy volunteers; they tested safety rather than injury healing [16][17].

Holding the actin pool. Tβ4 is a 5 kDa peptide that binds actin monomers and keeps them from polymerizing. In resting human neutrophils it is present at roughly 169 fg per cell, about 149 ± 80.5 µM in the cytoplasm, and on native gels most of the free actin in resting-cell extracts runs at the mobility of the actin-Tβ4 complex. Stimulating the cells with a chemoattractant reduces that complex. Comparing how strongly extracts from resting and stimulated cells suppress pyrene-actin polymerization shows the peptide releasing actin as filaments form, without any change in its affinity for the monomer, and its binding kinetics are fast enough to keep up with the polymerization and depolymerization cells do in life. So the protein is a buffer on the free actin pool rather than a signal: it holds monomers ready and gives them up when the cell needs to move [18].

Different jobs in different fragments. Three active sites have been mapped. The N-terminal four amino acids, Ac-SDKP, mainly block inflammation and fibrosis. The N-terminal 15 amino acids, which contain Ac-SDKP, promote cell survival and block apoptosis. The central actin-binding stretch LKKTETQ (residues 17-23 plus a glutamine) promotes angiogenesis, wound healing and cell migration - this is the fragment TB-500 is built on. Other activities have not been localized to any fragment: antimicrobial action, and the induction of laminin-5, matrix metalloproteinases, TGF-β, zyxin, terminal deoxynucleotidyl transferase and angiogenesis-related proteins [1].

In the heart. Tβ4 promoted migration of myocardial and endothelial cells in the embryonic mouse heart and kept that property in postnatal cardiomyocytes, and improved their survival in culture. It formed a functional complex with PINCH and integrin-linked kinase, which activated the survival kinase Akt. After coronary artery ligation in mice, treatment raised ILK and Akt activity in the heart, improved early myocyte survival and improved cardiac function [4]. This is the result the intravenous human safety program was built on, and it is why both phase 1 studies name acute myocardial infarction as the target indication [16][17].

In wounds. Reviews describe the peptide being released by platelets and macrophages after injury, mobilizing and differentiating stem and progenitor cells, and reducing the number of myofibroblasts in a wound, which means less scarring and fibrosis [19].

In the intravenous studies, adverse events were infrequent and mild to moderate, with no dose-limiting toxicity or serious adverse events [16][17]. Anti-drug antibodies were rare with the recombinant version [17]. The dry-eye trials reported the drops as safe and well tolerated [8][14].

Because Tβ4 promotes cell migration and blood-vessel growth, its link with cancer is worth knowing. It is expressed in most colorectal cancers, most strongly at the invasive front [20]. Pancreatic cancer cells make more of it than normal cells, and added Tβ4 raised their inflammatory cytokine output [21]. These are associations and lab findings, not evidence that taking Tβ4 causes cancer.

It is prohibited by the World Anti-Doping Agency, which lists it among growth factors affecting muscle, tendon and ligament repair [9].